

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.
RLL-475US

In Re Application Of: **SINGH et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/596,013	May 25, 2006	TBA	26815	TBA	TBA

Title: **PHARMACEUTICAL COMPOSITIONS COMPRISING NATEGLINIDE AND A SURFACTANT**

Address to:
**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-475US

In Re Application of: SINGH et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/596,013	May 25, 2006	TBA	26815	TBA	TBA

Title: PHARMACEUTICAL COMPOSITIONS COMPRISING NATEGLINIDE AND A SURFACTANT

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912
as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa
 (Date)
 Signature
 Typed or Printed Name of Person Signing Certificate


*This certificate may only be used if paying by deposit account.


Signature

William D. Hare, Esq.
Reg. No. 44,739

Customer No. 26,815

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class ^{Express} mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on
 January 23, 2007
 (Date)
  Signature of Person Mailing Correspondence
 Michelle Morgan
 Typed or Printed Name of Person Mailing Certificate

Dated: January 23, 2007

CC:

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-475US	Serial No.: 10/596,013
	Applicants: SINGH <i>et al.</i>	
	Filed: 5/25/2006	Group:

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	6,559,188	5/6/2003	Gatlin <i>et al.</i>	514	641	
	A2	2003/0021843	1/30/2003	Makino <i>et al.</i>	424	468	
	A3	2004/002544	1/1/2004	Makino <i>et al.</i>	514	563	

FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	B1	EP 0 128 249	12/19/1984	EPO	C07K	5/06	
	B2	EP 0 196 222	10/1/1986	EPO	C07C	233/81	
	B3	EP 0 526 171	2/3/1993	EPO	C07C	233/63	
	B4	EP 1 334 720	8/13/2003	EPO	A61K	31/198	
	B5	EP 1 334 721	8/13/2003	EPO	A61K	31/198	
	B6	WO 2005/020979	3/10/2005	PCT	A61K	31/198	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	C1	JP Stanley, "The Theory and Practice of Industrial Pharmacy", 2nd Edition, pgs. 108-109, Lackman et al. (eds), Lea & Febiger (pub), Philadelphia, PA (1976)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	